Auswahl der wissenschaftlichen Literatur zum Thema „He53“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "He53" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "He53"
Kent, Matthew R., Delia Calderon, Katherine M. Silvius, Jack P. Kucinski, Collette A. LaVigne, Matthew V. Cannon und Genevieve C. Kendall. „Abstract 3533: Zebrafish her3 knockout impacts developmental and rhabdomyosarcoma-related gene signatures“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3533. http://dx.doi.org/10.1158/1538-7445.am2023-3533.
Der volle Inhalt der QuelleBeckford Vera, Denis, Jason Li, Le-Cun Xu, Debbie Lewis, Amanda Chin, Patrik Brodin, Mary Chen, Monideepa Roy und Helen Kotanides. „Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): e15114-e15114. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15114.
Der volle Inhalt der QuelleKoyama, Kumiko, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Yang Qiu, Kenji Nakamaru und Masato Murakami. „Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression“. PLOS ONE 17, Nr. 5 (03.05.2022): e0267027. http://dx.doi.org/10.1371/journal.pone.0267027.
Der volle Inhalt der QuelleKomatsu, Nagiho, Saori Sato, Sumie Muramatsu, Ryuichi Nakamura und Kumiko Koyama. „Abstract 3996: The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody-drug conjugate“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3996. http://dx.doi.org/10.1158/1538-7445.am2023-3996.
Der volle Inhalt der QuelleO'Hare, Thomas, Jaclyn Cleveland, Valerie M. Jansen und David Dornan. „Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 3121. http://dx.doi.org/10.1158/1538-7445.am2024-3121.
Der volle Inhalt der QuelleBeckford-Vera, Denis, Megan McCloskey, Jason Li, Caroline Jennings, Le-Cun Xu, Debbie Lewis, Patrik Brodin et al. „Abstract 5040: Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5040. http://dx.doi.org/10.1158/1538-7445.am2023-5040.
Der volle Inhalt der QuelleToy, Weiyi, Dipti Thakkar, Roberto Magallanes, Sharon Wu, Ming Poi, Alejandro Mas, Konrad Paszkiewicz, Piers Ingram und Jerome Boyd-Kirkup. „Abstract 5796: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 5796. http://dx.doi.org/10.1158/1538-7445.am2024-5796.
Der volle Inhalt der QuelleBeckford-Vera, Denis, Jason Li, Megan McCloskey, Caroline Jennings, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen und Helen Kotanides. „Abstract 3306: Targeting HER3 receptor positive cancers with a novel anti-HER3 antibody radioconjugate (ARC)“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 3306. http://dx.doi.org/10.1158/1538-7445.am2022-3306.
Der volle Inhalt der QuelleScartozzi, M., A. Mandolesi, R. Giampieri, A. Zaniboni, E. Galizia, L. Giustini, R. R. Silva, R. Berardi, I. Bearzi und S. Cascinu. „The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab.“ Journal of Clinical Oncology 29, Nr. 4_suppl (01.02.2011): 404. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.404.
Der volle Inhalt der QuelleMartinez Lago, Nieves, Ihab Abdulkader, Dora Insua Santamaria, Patricia Viaño Nuñez, Juan Jose Carrera, Jose Ramón Antunez Lopez, Maria Elena Padin Iruegas und Rafael López López. „Assessment and prognostic impact of a new classification using HER2 and HER3 status in resected gastric cancer in a european cohort.“ Journal of Clinical Oncology 36, Nr. 4_suppl (01.02.2018): 65. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.65.
Der volle Inhalt der QuelleDissertationen zum Thema "He53"
BON, GIULIA. „Dual targeting of HER3 and MEK may overcome HER3-dependent chemoresistance of colon cancers“. Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2013. http://hdl.handle.net/2108/202145.
Der volle Inhalt der QuelleAldana, Hidalgo Julio Xavier, Parodi Augusto José Amador, Palacios Jorge Martin Arredondo, Aguilar Carla Barrionuevo, Ortiz Carol Elizabeth Beltrán, Fuentes Carlos Arturo Capellino, Alcazar Martin Roberto Cervetto et al. „Estrategias de redacción - HE59 201801“. Universidad Peruana de Ciencias Aplicadas (UPC), 2018. http://hdl.handle.net/10757/624389.
Der volle Inhalt der Quelle(UPC), Universidad Peruana de Ciencias Aplicadas, und Celis Ingunza Sandy Cecilia. „Creatividad Y Liderazgo-HE50-201601“. Universidad Peruana de Ciencias Aplicadas (UPC), 2016. http://hdl.handle.net/10757/639326.
Der volle Inhalt der Quelle(UPC), Universidad Peruana de Ciencias Aplicadas, und Garcia Soria Juddy Grethel Nora. „Creatividad Y Liderazgo-HE50-201602“. Universidad Peruana de Ciencias Aplicadas (UPC), 2016. http://hdl.handle.net/10757/639327.
Der volle Inhalt der Quelle(UPC), Universidad Peruana de Ciencias Aplicadas, und Ilizarbe Jurado Anndy Antonio. „Creatividad Y Liderazgo-HE50-201701“. Universidad Peruana de Ciencias Aplicadas (UPC), 2017. http://hdl.handle.net/10757/639328.
Der volle Inhalt der QuelleBass, Tarek. „Affibody molecules targeting HER3 for cancer therapy“. Doctoral thesis, KTH, Proteinteknologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-204593.
Der volle Inhalt der QuelleQC 20170330
Htun, van der Horst Edward. „The role of ErbB3/HER3 in gliomas and breast cancer“. Diss., lmu, 2002. http://nbn-resolving.de/urn:nbn:de:bvb:19-5804.
Der volle Inhalt der QuelleClaus, J. „The pseudokinase HER3 : structure/function relationships and inhibitor-induced signalling“. Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1457524/.
Der volle Inhalt der QuelleFranks, P. W. „A He3 magnetometer for the EDM experiment“. Thesis, University of Sussex, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.304321.
Der volle Inhalt der QuelleXie, Ting. „Targeting `Undruggable' Cancer Proteins with Irreversible Small Molecule Inhibitors: Her3 and KRas“. Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11384.
Der volle Inhalt der QuelleChemistry and Chemical Biology
Bücher zum Thema "He53"
cai, Jin sheng. Ping di ke ^wei guan jing ji xue~ (di4 he5 ban) bi ji he ke hou xi ti xiang jie. Bei jing: Zhong guo shi hua chu ban she, 2006.
Den vollen Inhalt der Quelle findenKay, Bartholomew L., Hrsg. Planning health promotion programs: An intervention mapping approach. San Francisco: Jossey-Bass, 2006.
Den vollen Inhalt der Quelle findenSole, Kathy. Making Connections: Understanding Interpersonal Communications. Zovio Inc., 2011.
Den vollen Inhalt der Quelle findenMaking Meaning, Making Sense: Children's Early Language Learning. Zovio Inc., 2012.
Den vollen Inhalt der Quelle findenFinancial Management of Health Care Organizations: An Introduction to Fundamental Tools, Concepts and Applications. Wiley & Sons, Incorporated, John, 2020.
Den vollen Inhalt der Quelle findenFinancial Management of Health Care Organizations: An Introduction to Fundamental Tools, Concepts and Applications. Wiley & Sons, Limited, John, 2020.
Den vollen Inhalt der Quelle findenKaya, Gökalp. He3. Independently Published, 2020.
Den vollen Inhalt der Quelle findenFischer, Benjamin. He3 the Novel. Independently Published, 2017.
Den vollen Inhalt der Quelle findenHe3: The Novel. Independent Publisher, 2010.
Den vollen Inhalt der Quelle findenPopkin, Michael H. Preparation for Active Parenting/He23. South-Western Pub, 1988.
Den vollen Inhalt der Quelle findenBuchteile zum Thema "He53"
Lugovskoy, Alexey, Michael Curley, Johanna Lahdenranta, Ashish Kalra, Akos Czibere, Gavin MacBeath und Birgit Schoeberl. „HER3“. In Cancer Therapeutic Targets, 719–37. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-0717-2_95.
Der volle Inhalt der QuelleLugovskoy, Alexey, Michael Curley, Johanna Lahdenranta, Ashish Kalra, Akos Czibere, Gavin MacBeath und Birgit Schoeberl. „HER3“. In Cancer Therapeutic Targets, 1–19. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-6613-0_95-1.
Der volle Inhalt der QuelleMacLeod, Sheena H., Kyle G. Potts, Shyambabu Chaurasiya und Mary M. Hitt. „Assessment of Specificity of an Adenovirus Targeted to HER3/4“. In Methods in Molecular Biology, 275–93. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7219-7_18.
Der volle Inhalt der QuelleHeindler, Manfred. „Feasibility, Safety and Environmental Aspects of D-He3 Fusion“. In Safety, Environmental Impact, and Economic Prospects of Nuclear Fusion, 173–79. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0619-1_11.
Der volle Inhalt der QuelleKartavtsev, O. I. „Universal description of the He3 system at low energy“. In Few-Body Problems in Physics ’98, 199–202. Vienna: Springer Vienna, 1999. http://dx.doi.org/10.1007/978-3-7091-6798-4_33.
Der volle Inhalt der QuelleRostoker, Norman, und Michl Binderbauer. „Self-Colliding Beams as an Alternative Fusion System for D-He3 Reactors“. In Current Trends in International Fusion Research, 33–41. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5867-5_4.
Der volle Inhalt der QuelleMoldover, M. R., und W. A. Little. „Specific Heat of He3 and He4 in the Neighborhood of their Critical Points“. In From High-Temperature Superconductivity to Microminiature Refrigeration, 53–55. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-0411-1_7.
Der volle Inhalt der QuelleSarkar, Mitul, und John G. Koland. „Fluorescence Recovery After Photobleaching Analysis of the Diffusional Mobility of Plasma Membrane Proteins: HER3 Mobility in Breast Cancer Cell Membranes“. In Methods in Molecular Biology, 97–105. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3170-5_9.
Der volle Inhalt der Quelle„HER3“. In Encyclopedia of Cancer, 1680. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_2678.
Der volle Inhalt der QuelleHesketh, Robin. „HER3/ERbB-3“. In The Oncogene & Tumour Suppressor Gene Factsbook, 212–15. Elsevier, 1997. http://dx.doi.org/10.1016/b978-012344548-3/50043-1.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "He53"
Chen, Min. „Influence of Helium Cluster Structure on Diffusion Behavior“. In 2013 21st International Conference on Nuclear Engineering. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/icone21-15478.
Der volle Inhalt der QuelleKol, Arjan, Martin Pool, Steven de Jong, Elisabeth GE de Vries, Marjolijn N. Lub-de Hooge und Anton GT Terwisscha van Scheltinga. „Abstract LB-B11: Assessment of HER3 status during lapatinib treatment in HER3-positive breast cancer using 89Zr-anti-HER3 mAb“. In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-lb-b11.
Der volle Inhalt der QuelleHettmann, Thore, Matthias Schneider, Selam Ogbagabriel, Jiansong Xie, Gloria Juan, Susanne Hartmann, Robert Radinsky und Daniel J. Freeman. „Abstract LB-306: U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation“. In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-306.
Der volle Inhalt der QuelleGhoranneviss, Mahmoud, Babak Malekynia, Nader Azizi, Henrich Hora und George H. Miley. „Alternative Laser Driven Fusion Reactions for Nuclear Energy Without Radioactivity“. In 18th International Conference on Nuclear Engineering. ASMEDC, 2010. http://dx.doi.org/10.1115/icone18-29945.
Der volle Inhalt der Quelle„HE3: power measurements“. In Proceedings of the 21st IEEE Instrumentation and Measurement Technology Conference. IEEE, 2004. http://dx.doi.org/10.1109/imtc.2004.1351506.
Der volle Inhalt der Quelle„HE5: temperature measurement“. In Proceedings of the 21st IEEE Instrumentation and Measurement Technology Conference. IEEE, 2004. http://dx.doi.org/10.1109/imtc.2004.1351517.
Der volle Inhalt der QuellePinzon-Ortiz, Maria C., Xianhui Rong, Richard Versace, Qing Sheng und Z. Alexander Cao. „Abstract 5320: Targeting HER3 and EGFR in NRG1 positive and HER3 mutated lung squamous cell carcinoma“. In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5320.
Der volle Inhalt der QuelleMukherjee, A., Y. Badal, X. Nguyen, J. Miller, S. Pidaparthi, L. Chen, A. Newton, J. Cheung, G. Parry und S. Williams. „Proximity-based assays for the detection of activated HER3, HER2/HER3 heterodimers and HER3/PI3K complexes in formalin-fixed, paraffin-embedded cell line controls and tumors.“ In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-4040.
Der volle Inhalt der QuelleZhang, Weixing, Way Kuo und Victor M. Tamashunas. „Simulating the (HE3/HE3/S):(PRP/ ∞ / ∞) queuing model for a maintenance problem“. In the 17th conference. New York, New York, USA: ACM Press, 1985. http://dx.doi.org/10.1145/21850.253317.
Der volle Inhalt der QuelleGarrett, Joan T., Cammie R. Sutton, Carl Uli Bialucha, Seth A. Ettenberg, Jerry Wallweber, Lisa DeFazio-Eli und Carlos L. Arteaga. „Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5461.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "He53"
Lyerly, H. K. Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2014. http://dx.doi.org/10.21236/ada612924.
Der volle Inhalt der QuelleLyerly, H. K. Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2013. http://dx.doi.org/10.21236/ada597890.
Der volle Inhalt der QuelleDittrich, T. R., B. A. Hammel und C. J. Keane. Diagnosis of pusher-fuel mix in indirectly driven Nova implosions (HEP3). Office of Scientific and Technical Information (OSTI), Juni 1996. http://dx.doi.org/10.2172/376961.
Der volle Inhalt der QuelleOng, Nai P. Acquisition of He3 Cryostat Insert for Experiments on Topological Insulators. Fort Belvoir, VA: Defense Technical Information Center, Januar 2016. http://dx.doi.org/10.21236/ad1007436.
Der volle Inhalt der QuelleTrichtchenko, L., L. Nikitina und M. Harrison. Statistical analysis of space environment on highly elliptical orbits. HEO1 and HEO3 missions data. Natural Resources Canada/ESS/Scientific and Technical Publishing Services, 2013. http://dx.doi.org/10.4095/292717.
Der volle Inhalt der Quelle